RVLP - InvestorNewsBreaks - RVL Pharmaceuticals plc (NASDAQ: RVLP) Spotlighted in New Cantor Fitzgerald Research Brief
RVL Pharmaceuticals (NASDAQ: RVLP), a specialty pharmaceutical company focused on the commercialization of UPNEEQ(R) (oxymetazoline hydrochloride ophthalmic solution) (“UPNEEQ”), 0.1%, for the treatment of acquired blepharoptosis, or low-lying eyelid, in adults, is featured in a recent Cantor Fitzgerald research brief. Noting that the stock “looks even more interesting post solid quarter and ahead of potential strategic acquisition,” the research brief reiterated its previous Overweight (“OW”) rating and 12-month price target of $6 for RVL Pharmaceutical shares, stating that RVLP’s commercial opportunities continue to be underappreciated and that upward earnings estimate revisions should drive the stock higher. The brief noted that RVLP’s prescription eye drop, UPNEEQ 0.1%, had been selected the winner in the professional treatment category as “Best Eye Drop for Drooping Lids” in the NewBeauty annual beauty awards, and that the company is in discussions with strategic targets that could accelerate UPNEEQ sales, broaden RVLP’s portfolio and leverage the field force investment.
“RVLP said it is in advanced discussions with certain companies that it could potentially partner with or acquire to support growth and integrate into its infrastructure with meaningful synergies,” stated the Cantor Fitzgerald report. “RVLP [also] reported second quarter 2023 UPNEEQ net product sales of $8.3 million and operating expenses of $14.4 million, down 2% and 32%, year over year, respectively. RVLP highlighted its lower baseline of operating expenses. It streamlined its operating expenses to extend its cash runway, optimize its marketing mix and support strategic business development. This streamlining had a modest unfavorable impact on sales during the quarter. And at 6/30/23, the company had cash and cash equivalents of $19.2 million and senior secured indebtedness with aggregate principal maturities of $70.7 million.”
To view the full press release, visit https://ibn.fm/B1Eph
About RVL Pharmaceuticals plc
RVL Pharmaceuticals plc is a specialty pharmaceutical company focused on the commercialization of UPNEEQ (oxymetazoline hydrochloride ophthalmic solution), 0.1%, for the treatment of acquired blepharoptosis, or low-lying eyelid, in adults. UPNEEQ is the first nonsurgical treatment option approved by the FDA for acquired blepharoptosis. For additional information about this company, please visit www.RVLPharma.com.
About InvestorWire
InvestorWire is the wire service that gives you more. From regional releases to global announcements presented in multiple languages, we offer the wire-grade dissemination products you’ll need to ensure that your next press release grabs the attention of your target audience and doesn’t let go. While our competitors look to nickel and dime you with hidden fees and restrictive word limits, InvestorWire keeps things transparent.
As part of its service, InvestorWire provides coverage of noteworthy announcements. To further expand visibility of achievements being made throughout a multitude of sectors, InvestorWire’s syndication partners have extended the digital coverage to include individual broadcasts on financial websites and platforms visited by millions of investors daily.
For more information, please visit https://www.InvestorWire.com
Please see full terms of use and disclaimers on the InvestorBrandNetwork website applicable to all content provided by IBN, wherever published or re-published: http://ibn.fm/Disclaimer
InvestorWire (IW)
8033 Sunset Blvd Suite 1037-IW
Los Angeles, CA 90046
310.299.1717 Office
www.InvestorWire.com
Editor@NetworkNewsWire.com
InvestorWire is part of the InvestorBrandNetwork.